Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 10/2014

01-10-2014 | Clinical Trial Report

Mast Cell Infiltration and Obesity-Related Glomerulopathy: an Under-Recognized Disease Process and New Ways to Approach Treatment

Authors: Mihran Naljayan, Efrain Reisin

Published in: Current Hypertension Reports | Issue 10/2014

Login to get access

Excerpt

Wang X, Chen H, Zhang M, Liu Z. Roles of mast cells and monocyte chemoattractant protein-1 in the renal injury of obesity-related glomerulopathy. American Journal of the Medical Sciences 2013 October; 346(4):295–301. doi: 10.​1097/​MAJ.​0b013e31827559f8​ …
Literature
1.
Wang X, Chen H, Zhang M, Liu Z. Roles of mast cells and monocyte chemoattractant protein-1 in the renal injury of obesity-related glomerulopathy. Am J Med Sci. 2013;346(4):295–301.PubMedCrossRef
2.
Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int. 2004;65(1):116–28.PubMedCrossRef
3.
Giunti S, Barutta F, Perin PC, Gruden G. Targeting the MCP-1/CCR2 system in diabetic kidney disease. Curr Vasc Pharmacol. 2010;8(6):849–60.PubMedCrossRef
4.
Colvin RB, Dvorak AM, Dvorak HF. Mast cells in the cortical tubular epithelium and interstitium in human renal disease. Hum Pathol. 1974;5(3):315–26.PubMedCrossRef
5.•
Hiromura K, Kurosawa M, Yano S, Naruse T. Tubulointerstitial mast cell infiltration in glomerulonephritis. Am J Kidney Dis. 1998;32(4):593–9. This study is of importance because it shows mast cell infiltration as an etiology for renal disease.PubMedCrossRef
6.
Kondo S, Kagami S, Kido H, Strutz F, Muller GA, Kuroda Y. Role of mast cell tryptase in renal interstitial fibrosis. J Am Soc Nephrol. 2001;12(8):1668–76.PubMed
7.
Irani AM, Bradford TR, Kepley CL, Schechter NM, Schwartz LB. Detection of MCT and MCTC types of human mast cells by immunohistochemistry using new monoclonal anti-tryptase and anti-chymase antibodies. J Histochem Cytochem. 1989;37(10):1509–15.PubMedCrossRef
8.••
Kambham N, Markowitz GS, Valeri AM, Lin J, D’Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001;59(4):1498–509. This study is of major importance in illustrating the obesity epidemic, as well as the increased incidence of ORG.PubMedCrossRef
9.
Chen HM, Li SJ, Chen HP, Wang QW, Li LS, Liu ZH. Obesity-related glomerulopathy in china: a case series of 90 patients. Am J Kidney Dis. 2008;52(1):58–65.PubMedCrossRef
10.
Jones SE, Kelly DJ, Cox AJ, Zhang Y, Gow RM, Gilbert RE. Mast cell infiltration and chemokine expression in progressive renal disease. Kidney Int. 2003;64(3):906–13.PubMedCrossRef
11.•
Shen WW, Chen HM, Chen H, Xu F, Li LS, Liu ZH. Obesity-related glomerulopathy: body mass index and proteinuria. Clin J Am Soc Nephrol. 2010;5(8):1401–9. This study focuses on weight loss as playing a major role in reversal of the proteinuria in ORG as opposed to pharmacotherapy that is often applied to proteinuric states.PubMedCrossRefPubMedCentral
Metadata
Title
Mast Cell Infiltration and Obesity-Related Glomerulopathy: an Under-Recognized Disease Process and New Ways to Approach Treatment
Authors
Mihran Naljayan
Efrain Reisin
Publication date
01-10-2014
Publisher
Springer US
Published in
Current Hypertension Reports / Issue 10/2014
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-014-0480-6

Other articles of this Issue 10/2014

Current Hypertension Reports 10/2014 Go to the issue

Blood Pressure Monitoring and Management (G Ogedegbe and JA Staessen, Section Editors)

Psychosocial Risk Factors for Hypertension: an Update of the Literature

Prevention of Hypertension: Public Health Challenges (P Muntner, Section Editor)

Ambulatory Blood Pressure Phenotypes and the Risk for Hypertension

Resistant Hypertension (E Pimenta, Section Editor)

Resistant or Refractory Hypertension: Are They Different?

Preeclampsia (VD Garovic, Section Editor)

Hypertensive Pregnancy Disorders and Future Renal Disease

Pathogenesis of Hypertension (W Elliott, Section Editor)

Obstructive Sleep Apnea and Hypertension: a Critical Review

Secondary Hypertension: Nervous System Mechanisms (J Bisognano, Section Editor)

Anxiety in the “Age of Hypertension”
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits